Vontobel Holding Ltd. Makes New $1.30 Million Investment in Certara, Inc. (NASDAQ:CERT)

Vontobel Holding Ltd. purchased a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 121,550 shares of the company’s stock, valued at approximately $1,295,000. Vontobel Holding Ltd. owned about 0.08% of Certara as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CERT. Brown Brothers Harriman & Co. acquired a new position in Certara in the 3rd quarter valued at $27,292,000. Wasatch Advisors LP grew its holdings in Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after buying an additional 1,128,006 shares in the last quarter. Glenmede Trust Co. NA grew its holdings in Certara by 78.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock valued at $14,123,000 after buying an additional 530,598 shares in the last quarter. Finally, Kopion Asset Management LLC grew its holdings in Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after buying an additional 175,005 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

CERT has been the subject of a number of recent analyst reports. Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Barclays dropped their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Price Performance

Shares of CERT stock opened at $14.19 on Tuesday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.28 billion, a P/E ratio of -70.95, a P/E/G ratio of 9.33 and a beta of 1.57. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87. The business has a fifty day simple moving average of $12.15 and a 200 day simple moving average of $11.65.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.